Optimalization Of The Time And Dosage Of Vemurafenib In BRAF Positive Juvenile Patients With Refractory Histiocytosis
Latest Information Update: 13 Sep 2024
At a glance
- Drugs Vemurafenib (Primary)
- Indications Langerhans cell histiocytosis
- Focus Therapeutic Use
- Acronyms BRAVO
- 08 Aug 2024 Planned End Date changed from 23 Jun 2026 to 30 Mar 2026.
- 29 Apr 2021 New trial record